Released Mar 19, 2026, after the close
10-K filed Mar 19, 2026, 78 days after period end · 0001390478-26-000003
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$7.66M-$7.66M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,255,000N/M
Operating Cash Flowderived-$4,921,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 |
| Net Income | -$7.66M | -$6.74M | -$8.14M | -$9.12M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR